Efficacy and safety of dupilumab up to 52 weeks in adults and adolescents with eosinophilic oesophagitis (LIBERTY EoE TREET study): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
Marc E. Rothenberg(Cincinnati Children's Hospital Medical Center), Arsalan Shabbir(Northwestern University), Elizabeth Laws(Sanofi (United States)), Jennifer Maloney(Regeneron (United States)), Jennifer D. Hamilton(Regeneron (United States)), Albert J. Bredenoord(Universität Hamburg), Jonathan M. Spergel(Children's Hospital of Philadelphia), Alfredo J. Lucendo, Eric Mortensen(Regeneron (United States)), Margaret H. Collins, Leda Mannent(Sanofi (France)), Lila Glotfelty(Icahn School of Medicine at Mount Sinai), Eilish McCann(Northwestern University), Xia Liu(Regeneron (United States)), Xian Sun(Regeneron (United States)), Evan S. Dellon(University of North Carolina at Chapel Hill), Mirna Chehade(New York Proton Center), Ikuo Hirano(Northwestern University)
Cited by 100
Related Papers
Eosinophilic esophagitis: Updated consensus recommendations for children and adults
|Journal of Allergy and Clinical Immunology|2011|2.1k
Burden of Gastrointestinal Disease in the United States: 2012 Update
|Gastroenterology|2012|2k
Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2018
|Gastroenterology|2018|1.7k
Updated International Consensus Diagnostic Criteria for Eosinophilic Esophagitis: Proceedings of the AGREE Conference
|Gastroenterology|2018|1.1k
Burden of Gastrointestinal, Liver, and Pancreatic Diseases in the United States
|Gastroenterology|2015|996